Pascal Barneoud
Sanofi R&D
Chilly, 91380, France
Chilly, 91380, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration.
Journal: Neuropharmacology
Published: October 31, 2020
Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 08, 2020
Flexibility as a marker of early cognitive decline in humanized apolipoprotein E ε4 (ApoE4) mice.
Journal: Neurobiology of aging
Published: February 24, 2020
Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease.
Journal: PloS one
Published: July 17, 2019
Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease.
Journal: Data in brief
Published: February 02, 2019
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Journal: Bioorganic & medicinal chemistry letters
Published: October 23, 2018
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Journal: Alzheimer's research & therapy
Published: April 11, 2018
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: October 26, 2017
High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: October 17, 2017
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.
Journal: Glia
Published: September 22, 2017
NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration.
Journal: Neurobiology of disease
Published: December 13, 2016
Last Updated: 09/26/2026